利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.028 秒)

    PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA
    5.
    发明授权
    PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 有权
    药剂师ZUSAMMENSETZUNGEN MIT RESISTENZ GEGENLÖSLICHESCEA

    公开(公告)号：EP1976880B1

    公开(公告)日：2016-07-06

    申请号：EP06841112.3

    申请日：2006-12-21

    申请人： Amgen Research (Munich) GmbH

    发明人： LUTTERBÜSE, Ralf ,  MAYER, Petra ,  SCHALLER, Evelyne ,  RAU, Doris ,  MANGOLD, Susanne ,  KUFER, Peter ,  MURR, Alexander ,  WISSINGER, Monika ,  RAUM, Tobias

    IPC分类号： C07K16/24 ,  C07K16/30 ,  A61K39/395

    CPC分类号： C07K16/468 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2809 ,  C07K16/3007 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2319/00

    摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.

    摘要翻译： 本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含具有特异性结合人CD3的第一结合结构域的双特异性单链抗体和与人CEA特异性结合的第二结合结构域， 其中所述第二结合结构域包含鼠单克隆抗体A5B7的CDR-H3或完整CDR-H3的至少一部分。 此外，公开了用于生产所述药物组合物的方法以及具有对人CD3抗原和人CEA抗原具有特异性的特异性双特异性单链抗体分子的医学/药物用途。

    CROSS-SPECIES-SPECIFIC PSMAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
    6.
    发明授权
    CROSS-SPECIES-SPECIFIC PSMAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY 有权
    跨物种 - 分离器双相分离器PSMAXCD3-EINZELKETTENANTIKÖRPER

    公开(公告)号：EP2356153B1

    公开(公告)日：2016-05-04

    申请号：EP09783664.7

    申请日：2009-10-01

    申请人： Amgen Research (Munich) GmbH

    发明人： KUFER, Peter ,  RAUM, Tobias ,  KISCHEL, Roman ,  LUTTERBÜSE, Ralf ,  HOFFMANN, Patrick ,  RAU, Doris ,  MANGOLD, Susanne ,  KLINGER, Matthias ,  SCHALLER, Evelyne ,  HAUSMANN, Susanne ,  FLUHR, Petra ,  STEIGER, Carola

    IPC分类号： C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

    CPC分类号： C07K16/3069 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34

    摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

    摘要翻译： 本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分 身份证号 2,4,6和8以及能够结合前列腺特异性膜抗原（PSMA）的第二结合结构域。 本发明还提供编码所述双特异性单链抗体分子的核酸以及载体和宿主细胞及其生产方法。 本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

    CROSS-SPECIES-SPECIFIC BINDING DOMAIN
    8.
    发明公开
    CROSS-SPECIES-SPECIFIC BINDING DOMAIN 审中-公开

    公开(公告)号：EP3461842A1

    公开(公告)日：2019-04-03

    申请号：EP18184899.5

    申请日：2008-04-03

    申请人： Amgen Research (Munich) GmbH

    发明人： KUFER, Peter ,  RAUM, Tobias ,  KLINGER, Matthias ,  RAU, Doris ,  MANGOLD, Susanne ,  KISCHEL, Roman ,  LUTTERBÜSE, Ralf ,  HOFFMANN, Patrick

    IPC分类号： C07K16/28 ,  C07K16/46 ,  A61K39/395 ,  A61P35/00

    摘要： The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (CD3 epsilon).